Michel Jeannot
Pulmonary Disease · Loganville, GANPI 1700023330
Payments from drug & device makers
Across 327 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$880
- Jazz Pharmaceuticals Inc.$696
- Harmony Biosciences LLC$692
- AstraZeneca$685
- Regeneron Healthcare Solutions, Inc.$615
- GSK$581
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,70197%
- Education$1943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 41 | $880 |
| Jazz Pharmaceuticals Inc. | 28 | $696 |
| Harmony Biosciences LLC | 30 | $692 |
| AstraZeneca | 35 | $685 |
| Regeneron Healthcare Solutions, Inc. | 27 | $615 |
| GSK | 34 | $581 |
| Baxter Healthcare | 23 | $556 |
| Mylan Specialty L.p. | 16 | $295 |
| Sanofi | 13 | $288 |
| Grifols USA, LLC | 15 | $285 |
| Mallinckrodt Hospital Products Inc. | 7 | $171 |
| Advanced Respiratory, Inc | 6 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $129 |
| Sunovion Pharmaceuticals Inc. | 7 | $93 |
| Eisai Inc. | 5 | $87 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $73 |
| Shire North American Group Inc | 3 | $68 |
| Inspire Medical Systems, Inc. | 3 | $61 |
| Resmed Corp | 2 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $46 |
| Verona Pharma, Inc. | 2 | $44 |
| Merck | 3 | $43 |
| Electromed, Inc. | 2 | $33 |
| Olympus America Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| AbbVie | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| United Therapeutics Corporation | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Pulmonx Corporation | 1 | $18 |
| Viatris Specialty LLC | 1 | $16 |
| Circassia Inc. | 1 | $11 |
How this compares
$6,895 in reported general payments places this provider in the 55th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 31 | $574,769 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 370 | $254,368 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $109,266 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 105 | $55,290 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 90 | $43,685 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $39,798 |
| Spiriva RespimatTiotropium Bromide | 54 | $37,711 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $31,401 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $18,027 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 506 | $13,623 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $13,588 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $10,157 |
| EliquisApixaban | 14 | $8,703 |
| Spiriva HandihalerTiotropium Bromide | 11 | $6,371 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $5,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $581 | $343,735562 claims |
| Grifols USA, LLCProlastin C | $285 | $109,26611 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $880 | $106,590179 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $685 | $49,42890 claims |
| MerckBelsomra | $43 | $5,15812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Loganville
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.